What is the 13F Pro Quality Score for MBOT?

13F Pro ranks Microbot Medical Inc. (MBOT) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View MBOT's current score at https://13fpro.ai/research/MBOT (free sign-up required for the full ranking).

Where does 13F Pro source MBOT data?

All Microbot Medical Inc. fundamentals and ownership data come directly from SEC EDGAR. Microbot Medical Inc. files with the SEC under CIK 883975. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is MBOT in?

Microbot Medical Inc. (MBOT) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is MBOT research updated on 13F Pro?

MBOT's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Microbot Medical Inc.(MBOT)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 883975 MBOT stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $1.4M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

MBOT Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Microbot Medical Inc. (MBOT), a Healthcare sector company. MBOT is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $1.4m in revenue. Based on the latest XBRL financial filings (Q1 2026), Microbot Medical Inc. reports quarterly revenue of $105.0K, net income of $-3.7M, free cash flow of $-5.2M. Top institutional holders of MBOT by reported 13-F value include VANGUARD CAPITAL MANAGEMENT, CIBC Bancorp USA, SUSQUEHANNA INTERNATIONAL GROUP, LLP, based on the most recent SEC filings. MBOT trades on the Nasdaq exchange and files with the SEC under CIK 883975. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MBOT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Microbot Medical Inc. directly from SEC EDGAR.

Revenue

Q1 2026

$105.0K

Net Income

Q1 2026

$-3.7M

Free Cash Flow

Q1 2026

$-5.2M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Net Income

-14.8% YoY

$-13.1MFY 2025

FY22 $-13.2MFY23 $-10.7MFY24 $-11.4MFY25 $-13.1M

Operating Income

-26.8% YoY

$-14.7MFY 2025

FY22 $-13.3MFY23 $-9.9MFY24 $-11.6MFY25 $-14.7M

EPS (Diluted)

+60.3% YoY

$-0.29FY 2025

FY22 $-1.81FY23 $-1.05FY24 $-0.73FY25 $-0.29

Total Assets

+1252.1% YoY

$81.5MFY 2025

FY22 $9.5MFY23 $8.3MFY24 $6.0MFY25 $81.5M

Op. Cash Flow

-47.8% YoY

$-13.0MFY 2025

FY22 $-11.5MFY23 $-8.5MFY24 $-8.8MFY25 $-13.0M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2019
Net Income	$-13.1M -14.8%	$-11.4M -6.5%	$-10.7M +18.4%	$-13.2M -16.4%	$-11.3M -56.1%	$-7.2M
Operating Income	$-14.7M -26.8%	$-11.6M -18.0%	$-9.9M +25.8%	$-13.3M -16.9%	$-11.4M -56.9%	$-7.2M
EPS (Diluted)	$-0.29 +60.3%	$-0.73 +30.5%	$-1.05 +42.0%	$-1.81	—	—
Total Assets	$81.5M +1252.1%	$6.0M -27.6%	$8.3M -12.7%	$9.5M -43.1%	$16.8M -54.8%	$37.1M
Operating Cash Flow	$-13.0M -47.8%	$-8.8M -3.4%	$-8.5M +26.1%	$-11.5M -23.5%	$-9.4M -45.0%	$-6.5M

AI Insight: MBOT Financial Trends

Pre-revenue biotech burning cash consistently while equity base swelled then contracted, signaling dilution and capital constraints ahead.

• Revenue remains at $0M through Q1 2026; no commercialization yet. Operating losses stable at $3–4M per quarter.

• Equity surged from $4M (Q3 2024) to $78M (Q3 2025), then fell to $74M (Q1 2026)—likely equity raise followed by dilution.

• Operating cash flow consistently negative at $2–5M per quarter; no path to cash generation visible in dataset.

⚠ Equity erosion from $78M peak suggests accelerating cash burn or dilutive financing. Runway sustainability unclear.

⚠ No revenue reported across 9 quarters. Clinical/regulatory progress data needed to validate investment thesis.

AI Insight: MBOT Ratio Trends

Microbot Medical remains deeply unprofitable, with ROIC deteriorating to -23.3% in Q1 2026 despite recent stabilization in ROE and ROA.

• ROE improved sharply from -162.8% in Q2 2024 to -19.8% in Q1 2026, indicating reduced magnitude of losses relative to equity.

• ROIC worsened from -19.7% in Q3 2025 to -23.3% in Q1 2026, reversing three quarters of sequential improvement.

⚠ Company has not generated positive returns on equity, assets, or invested capital across entire nine-quarter window.

⚠ ROIC deterioration in latest quarter after three quarters of gains suggests momentum shift; requires investigation into capital deployment.

Get alerted when MBOT's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Microbot Medical Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of MBOT

VANGUARD CAPITAL MANAGEMENT LLC
$7.0M2,909,525 sh
CIBC Bancorp USA Inc.
$4.5M1,870,000 sh
SUSQUEHANNA INTERNATIONAL GROUP, LLP
$2.2M924,307 sh
BlackRock, Inc.
$2.1M857,398 sh
UBS Group AG
$2.0M816,945 sh
GEODE CAPITAL MANAGEMENT, LLC
$1.8M760,831 sh
DnB Asset Management AS
$1.6M677,498 sh
STIFEL FINANCIAL CORP
$1.4M573,075 sh
MARSHALL WACE, LLP
$1.2M481,045 sh
MILLENNIUM MANAGEMENT LLC
$1.1M454,746 sh

Fund	Value	Shares
VANGUARD CAPITAL MANAGEMENT LLC	$7.0M	2,909,525
CIBC Bancorp USA Inc.	$4.5M	1,870,000
SUSQUEHANNA INTERNATIONAL GROUP, LLP	$2.2M	924,307
BlackRock, Inc.	$2.1M	857,398
UBS Group AG	$2.0M	816,945
GEODE CAPITAL MANAGEMENT, LLC	$1.8M	760,831
DnB Asset Management AS	$1.6M	677,498
STIFEL FINANCIAL CORP	$1.4M	573,075
MARSHALL WACE, LLP	$1.2M	481,045
MILLENNIUM MANAGEMENT LLC	$1.1M	454,746

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put MBOT on your watchlist

Track score changes the day Microbot Medical Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is MBOT a good stock to buy?

13F Pro's AI-powered analysis of Microbot Medical Inc. (MBOT) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for MBOT are available on the MBOT stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own MBOT?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling MBOT. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Microbot Medical Inc.'s investment landscape.